Abstract

Objectives: To review the immunogenicity, safety and efficacy of inactivated and attenuated trivalent influenza vaccines in children.

Sources of data: Database search of the medical literature indexed on MEDLINE, LILACS and in the Cochrane Library. Review articles, clinical trials and epidemiological studies published from 1990 to 2006 were selected for analysis.

Summary of the findings: Influenza is an infectious disease that is both universal and seasonal, with incidence in all age groups and annual epidemics characterized by excessive morbidity and mortality. The elderly and people with comorbidity are high risk groups for severe influenza. It has recently been proven that healthy infants suffer similar morbidity to other risk groups, and therefore vaccination against influenza is indicated for them too, as being the most effective means of preventing infection by the influenza virus. The safety of influenza vaccines in children appears adequate, with the most often observed adverse effects being local reactions or fever. Immunogenicity in children varies from 30 to 90%, being directly proportional to age. Efficacy depends on the primary objective and can range from levels comparable with placebo to up to 91% efficacy against confirmed influenza A infection. Schoolchildren play an important role in the dissemination of the influenza virus, and population studies have demonstrated herd immunity.

Conclusions: Trivalent influenza vaccines, whether inactivated or attenuated, have low reactogenicity and offer variable immunogenicity and efficacy in children. Vaccination is effective for prevention of infections by the influenza virus and for reducing morbidity. More powerful studies of efficacy and safety in infants are still required.


Introduction

The influenza virus is the etiologic agent of the flu, causing annual epidemics which are associated with excessive hospitalizations and mortality, particularly among the elderly and those suffering from underlying conditions, such as cardiopulmonary and metabolic diseases and immunodeficiencies. Prevention of infection by the influenza virus by means of vaccination is recommended for all of these populations and their contacts and also anyone who does not wish to catch the flu.

Recently, the Advisory Committee on Immunization Practices (ACIP), in the USA, and the American Academy of Pediatrics recommended routine influenza vaccination for children aged 6 to 23 months, considering this age group to be at high risk of increased severity of infection by the influenza virus. This recommendation was based on epidemiological surveys that demonstrated that children in this age group exhibit hospitalization rates that are greater than or equal to those observed in other high risk groups. Furthermore, use of the inactivated influenza vaccine with children at this age has been proven to be safe and to have acceptable efficacy, backing up the recommendation. The Infectology Department of the Brazilian Society of Pediatrics also recommended the inclusion of influenza vaccination for children from 6 to 23 months in the vaccination schedule they presented at the XIV Brazilian Congress of Pediatric Infectology, held at Foz do Iguaçu (state of Paraná, Brazil) in April 2005. In the light of this recommendation, in conjunction with other significant epidemiological data on the role of children in the transmission, morbidity and mortality of influenza epidemics, it is considered appropriate to discuss the subject.
The objective of this review is to use medical literature and Brazilian epidemiological data to briefly characterize the impact of the flu and the benefits, immunogenicity, safety and efficacy of vaccinating healthy children against the influenza virus, especially in the 6 to 23 months age group.

Database searches were run on MEDLINE, LILACS and the Cochrane Library and specialists were consulted on the following themes: influenza, influenza vaccine, infants, vaccine efficacy and adverse events. The most relevant articles were selected from those that reported on randomized, double-blind and controlled clinical trials, in addition to national or international epidemiological population-based incidence studies.

Biology and epidemiology of the influenza virus

The influenza virus is an orthomyxovirus with an envelope and single-strand segmented RNA. It has two surface glycoproteins, which play important roles in its antigenicity and pathogenicity, named hemagglutinin (HA) and neuraminidase (NA). Influenza viruses are classified into one of three subtypes, A, B or C, with the first of these being associated with the greatest antigenic variation in HA and NA. Three HA (H1, H2 and H3) and two NA (N1 and N2) variants are associated with infections in human beings, although other variants, such as H5N1, that are typically observed in other species, have caused infections in humans who have had contact with poultry.

Influenza viruses cause annual epidemics that are associated with significant morbidity and mortality and have a major impact on public health, with around 20 thousand deaths/year and 140 thousand hospitalizations/year, on average, in the USA. The populations at greatest risk present more severe infections by the influenza virus and excessive levels of pneumonia, mortality and hospital admissions, particularly among the elderly, cardiopulmonary patients and people with immunodeficiencies.

In temperate countries and in the South and Southeast of Brazil, influenza virus epidemics typically occur during the winter months. In regions with tropical climates, however, they can happen at any time of year, sometimes more than once a year, and may be associated with rainy seasons. The circulation of the influenza virus is global and annual epidemics and pandemics are associated with population immunity to the subtype in circulation, with the epidemics being associated with small variations within a subtype (antigenic drift) and pandemics with major antigenic variation (antigenic shift).

Impact of the influenza virus on children

Glezen et al. described the typical progression of an influenza epidemic, with an average duration of 6 to 8 weeks, starting among schoolchildren and later passing to economically active adults. The role of children in the spread of these viruses is clear, having also been reported in more recent epidemiological studies.

Children do not only disseminate the influenza virus, but can also present significant morbidity associated with flu infections, with less typical and sometimes more severe clinical manifestations. Encephalitis cases caused by the influenza virus have been described in children, and in the USA, 121 deaths were associated with influenza infections in patients less than 18 years old, with just 26% of these having risk factors for greater severity.

The fact that hospital admissions among children under 5 years of age increase in frequency during influenza epidemics has been known for several years. Nevertheless, since the respiratory syncytial virus (RSV) is one of the principal agents of hospitalization in children less than 1 year old with lower respiratory tract infections, and since RSV exhibits similar seasonality to the influenza virus, the real importance of the influenza virus was initially undervalued in this age group. Later, Neuzil et al. demonstrated that the influenza virus was also associated with hospitalizations and morbidity to as significant an extent as RSV. These authors were able to characterize the varying periods of predominance of each agent and the rates of hospitalization associated with each one. Since then other studies have confirmed these authors' findings, demonstrating the true impact of influenza virus infections in children, associated with increased severity, increase in the number of medical consultations, use of antibiotics, parents' absenteeism from work and the appearance of secondary cases.

Acute respiratory infections are the most important cause of mortality in children under 5 years in developing countries. Despite bacterial etiology being considered more associated with mortality, viruses present very significant frequency and are associated with secondary infections. Kim et al. demonstrated an association between influenza epidemics and an increased number of identifications of pneumococcus in invasive infections, which was confirmed experimentally by Peltola et al. and by O'Brien et al. in case control studies of pneumococcal pneumonia. The experimental efficacy of vaccination and of treating influenza with antivirals for preventing mortality in mice by invasive pneumococcal infection were also recently confirmed.

The impact of the influenza virus on children in Brazil

Currently, the epidemiology of the influenza virus is well known in Brazil and its seasonality has been well characterized, with outbreaks taking place in the winter months in the South and Southeast regions. Brazil has referral centers for the diagnosis and identification of
Influenza viruses and is an active participant in the World Health Organization (WHO) influenza surveillance network, contributing with data to support the decision on the annual composition of the influenza vaccine to be used in the Southern Hemisphere. The morbidity of influenza virus infections in Brazilian children has not been analyzed systematically; however, there are several different published studies in which the influenza virus appears as a cause of acute respiratory infections and hospital admissions.15,38-46

In the Ribeirão Preto area (São Paulo state), an increase was observed in the number of hospitalizations due to pneumonia and bronchiolitis in children under 5 years of age during the months that correspond to the greatest incidence of RSV and the influenza virus.15,38 During an influenza outbreak in 2004, the virus was detected in 13% of children under 1 year old admitted to hospital for bronchiolitis or pneumonia,39 in addition to concomitant occurrence with severe pneumococcal pneumonia.40 Paiva et al.14 studied an influenza outbreak in Iporanga (São Paulo state) and observed that 84.3% of cases were in children and adolescents up to 19 years of age. Moura et al.41 detected the influenza virus in 22.3% of children under 5 years old seen at emergency and/or health centers in Salvador (Bahia state). In the same city, a longitudinal follow-up study of children seen at day care who had presented respiratory symptoms detected the influenza virus in 7% of cases.42 In Rio de Janeiro (Rio de Janeiro state), Sutmoller et al.43 and Nascimento et al.44 detected the influenza virus in 10 and 6.7% of children under 5 years old with acute respiratory infections (ARI), respectively. In Porto Alegre (Rio Grande do Sul state), Stralioto et al.45 detected the virus in 1.7% of children from 0 to 5 years old with ARI seen at an emergency room. In a longitudinal study of children with respiratory symptoms in the city of Fortaleza (Ceará state) Arruda et al.46 detected the influenza virus in 5.7% of patients with upper airway infections.

Even without the mass of epidemiological data available on North-America, we can infer that the influenza virus is an important causal agent of ARI in Brazilian children under 5 years old and that it is associated with increased hospital admissions for lower airway infections, with significant morbidity.

### Influenza vaccines

The different types of influenza vaccines are listed in Table 1 with their main characteristics, indications and course of doses. The vaccine presentations available in Brazil are listed in Table 2.

Inactivated vaccines are the primary means of preventing influenza infection, due to the vast experience of their use worldwide. Vaccines made with whole viruses exhibit good levels of immunogenicity, but have greater reactogenicity too, in particular causing fever in children and, therefore, are not indicated for this age group. Split vaccines, whether from fragmented or subunit viruses, offer a good safety profile, with the first being more immunogenic than the second and both being indicated for children under 12 years.8

Virosome vaccines are inactivated vaccines in which the HA and NA influenza virus surface antigens are incorporated into virosome (virus-like) particles that have an adjuvant role.47 This type of vaccine offers similar

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Type of virus</th>
<th>Composition</th>
<th>Indications</th>
<th>Course/Route</th>
<th>Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole viruses</td>
<td>Inactivated</td>
<td>Whole inactivated viruses</td>
<td>Over 12 years</td>
<td>1 dose IM</td>
<td>0.5 mL</td>
</tr>
<tr>
<td>Split</td>
<td>Inactivated</td>
<td>Split viruses (HA, NA and capsule)</td>
<td>From 6 months</td>
<td>1 or 2 IM doses *</td>
<td>0.25 mL (6 to 36 months) 0.5 mL (&gt; 3 years)</td>
</tr>
<tr>
<td>Subunit</td>
<td>Inactivated</td>
<td>HA and NA in isolation</td>
<td>From 6 months</td>
<td>1 or 2 doses</td>
<td>–</td>
</tr>
<tr>
<td>Virosome</td>
<td>Inactivated</td>
<td>HA and NA absorbed into virosome particles</td>
<td>From 6 months</td>
<td>1 IM dose</td>
<td>0.25 mL (6 to 36 m) 0.5 mL (&gt; 3 years)</td>
</tr>
<tr>
<td>Cold-adapted</td>
<td>Attenuated</td>
<td>Whole attenuated cold-adapted viruses</td>
<td>Healthy 5 to 49-year-olds</td>
<td>1 or 2 nasal doses</td>
<td>0.5 mL</td>
</tr>
</tbody>
</table>

HA = hemagglutinin; IM = intramuscular; NA = neuraminidase.

* 6 months to 9 years: two doses during the first year of immunization.

---

**Table 1 - Influenza vaccines**
immunogenicity and safety to other vaccines.\textsuperscript{47,48} A nasal formulation was used in a clinical trial with children and later abandoned due to a link with facial paralysis.\textsuperscript{48,49}

Recently, a trivalent, live, attenuated influenza vaccine (LAIV) was licensed in the USA.\textsuperscript{50} An attenuated vaccine had been previously used in the now-extinct USSR and had been studied in the USA since the 1960s, being now revisited with nasal administration.\textsuperscript{51,52} The vaccine that is currently licensed in the USA must be stored frozen at -15 °C and was approved for use with healthy children and adults from 5 to 49 years of age.\textsuperscript{50} The attenuated influenza vaccine was shown to be safe, immunogenic and effective, although there are doubts about its safety in small children, the elderly and patients with immunosuppression, despite having been tested in clinical trials with these populations.\textsuperscript{53-55} This vaccine can induce systemic humoral and mucosal immunorespons, in addition to cellular immunorespons, being capable of inducing cross-protection against other influenza strains.\textsuperscript{56} A liquid formulation that does not require freezing is currently in phase III clinical trials.\textsuperscript{57}

Safety of the influenza vaccines in children

The safety of trivalent inactivated and attenuated influenza vaccines has been tested in clinical trials and reviews of databases on vaccine-related adverse events.\textsuperscript{7} Neuzil et al.\textsuperscript{7} reviewed adverse reactions at a clinical research center in the USA over a 5-year period (1985-90) in 277 children aged 1 to 16 years who were given 635 doses of vaccine. No severe reactions were observed and local reactions occurred in 6 to 14% of those who were vaccinated. In another randomized, double-blind, placebo controlled multicenter study of 2,032 patients with asthma, 712 of whom were aged 3 to 18 years, no asthma exacerbations were observed among those vaccinated up to 2 weeks after vaccination.\textsuperscript{61}

Guillain-Barré syndrome has not been linked with the inactivated vaccine in children, but the relatively small number of patients in the studies compromise their power for detecting extremely rare events.\textsuperscript{7} Ruben\textsuperscript{8} revised all articles published on the inactivated influenza vaccine up to 2004, and described reactogenicity varying significantly between whole and split virus vaccines, with the latter

---

Table 2 - Influenza vaccines available in Brazil

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Type of virus</th>
<th>Composition</th>
<th>Presentation</th>
<th>Laboratory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaxigrip\textsuperscript{8}</td>
<td>Inactivated</td>
<td>Split viruses (HA, NA and capsule)</td>
<td>Multi-dose vial Single dose syringes, adult (0.5 mL) or pediatric (0.25 mL)</td>
<td>Sanofi-Pasteur</td>
</tr>
<tr>
<td>Fluarix\textsuperscript{8}</td>
<td>Inactivated</td>
<td>Split viruses (HA, NA and capsule)</td>
<td>0.5 mL vial</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Inactivated flu vaccine</td>
<td>Inactivated</td>
<td>Split viruses (HA, NA and capsule)</td>
<td>0.5 mL vial</td>
<td>CSL</td>
</tr>
<tr>
<td>Inflexal\textsuperscript{8}</td>
<td>Inactivated</td>
<td>HA and NA absorbed into virosome particles</td>
<td>0.5 mL vial</td>
<td>Berna</td>
</tr>
</tbody>
</table>

HA = hemagglutinin; NA = neuraminidase.
Immunogenicity

The majority of reactions were local or febrile and varied significantly between studies.

Smith et al.,62 in a review published by the Cochrane Library, confirmed that local reactions and fever were the most common adverse events after influenza vaccination, whether with inactivated or attenuated vaccine. The authors emphasized the scant experience from clinical trials with inactivated vaccines in children less than 2 years old, although clinical experience is relevant.

Recently, McMahon et al.63 performed a 14-year review, 12 years (1990 to 2002) before and 2 years (2002-2003) after the recommendation for vaccinating children under 24 months, using data from the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Report System (VAERS). The authors searched for reports of adverse reactions after vaccination with the inactivated influenza vaccine in children under 2 years old. They found reports of 166 events, 62 (37%) of which were related to influenza vaccine alone and 104 (63%) occurred after influenza vaccine was given together with other vaccines. Fever (59%) was the most common event, followed by rash (42%), convulsions (28%) and local reactions (28%).

It is estimated that in 2002/2003, around 424,667 to 513,403 children were vaccinated, with 61 reports of adverse events, with a frequency of 0.014 to 0.012%. Just 18 of these were associated with influenza vaccination alone, significantly reducing this rate to around 3:100,000 doses. These data are corroborated by information obtained from the São Paulo state health department, which also showed that reports of adverse events after influenza vaccination in children was not very representative (Sato HK, personal communication at a meeting of the Department of Infectious Diseases of Sociedade de Pediatria de São Paulo, held in São Paulo, SP, on August 8, 2005).

Izurieta et al.64 used the CDC VAERS system to review reports of adverse events in children and adults receiving the attenuated influenza vaccine during the period after its licensure, from 2003 to 2005. A total of 2.5 million people were vaccinated, with 460 adverse events reported, including seven reports of anaphylactic shock, two of Guillain-Barré syndrome, one of facial paralysis and eight asthma exacerbations. In 16% of the adverse event reports the vaccine had been given to patients for whom it was not indicated, i.e. healthy individuals aged 5 to 49 years. These data corroborate previous observations made in clinical trials that characterized the attenuated influenza vaccine as safe.52,55 In a clinical trial conducted by Piedra et al.,53 the attenuated vaccine demonstrated a satisfactory safety profile, including in the children under 5 years of age.

Efficacy of the influenza vaccine in children

The results of clinical trials investigating the efficacy of the inactivated influenza vaccine vary greatly, depending on the primary objective of each study.8 In general, efficacy against confirmed influenza virus infection varies from 31 to 91% and is not uniform for the subtypes. Protective efficacy for acute otitis media (AMO) is more variable, being reported as absent by some authors and up to 36% by others.

Hurwitz et al.71 studied the inactivated influenza vaccine in 150 children from 2 to 5 years old who attended daycare. Protective efficacy against influenza infections, confirmed by serology, was 45% for influenza virus B and 31% influenza virus A. Prevention of acute febrile flu-like disease was studied by Colombo et al.72 in 344 healthy children aged 1 to 6 years, in a randomized, controlled trial. The vaccinated group (n = 177) exhibited a 67% reduction in episodes of acute febrile disease when
compared with the control group (n = 167) (12.4 vs. 37.7%, respectively).

In a review of clinical trials conducted from 1985 to 1990, Neuzil et al.\textsuperscript{73} studied the efficacy of the inactivated influenza vaccine in healthy children less than 16 years old. With the primary outcome of protection against influenza infections confirmed by culture, efficacy was 77 to 91% against the A/H3N2 and A/H1N1 influenza viruses, respectively. Clements et al.,\textsuperscript{76} in a retrospective study of 83% (3 vs. 29%, vaccinated and unvaccinated, respectively) in asthmatic individuals.

Hoberman et al.,\textsuperscript{74} studied the protective efficacy against AMO of the inactivated influenza vaccine in children from 6 to 24 months who attended daycare during two flu seasons. The authors did not observe differences between the vaccinated group and a placebo group, but up to 66% protection from influenza infections was observed, confirmed by culture. Heikkinen et al.,\textsuperscript{75} assessed children from 1 to 3 years of age with n = 187 in each group, vaccinated and unvaccinated respectively, and observed a reduction of 36% in AMO episodes (34 vs. 53%, vaccinated vs. unvaccinated). The same study reported protective efficacy against confirmed influenza A infection of 83% (3 vs. 29%, vaccinated and unvaccinated, respectively). Clements et al.,\textsuperscript{76} in a retrospective study of 186 children from 6 to 30 months de age, reported reductions of 32% in AMO episodes.

Kramarz et al.,\textsuperscript{77} reported efficacy in asthma patients for reducing asthma exacerbations after vaccination with the inactivated influenza vaccine. Sugaya et al.,\textsuperscript{78} reported 67 and 44% protection against influenza A and B, respectively, in asthmatic individuals.

A study of attenuated influenza vaccine carried out by Belshe et al.,\textsuperscript{52} found efficacy of 87 to 93% against confirmed infection by the influenza A virus the first year of vaccination and 86 to 87% the second year, when the strain of influenza A virus in circulation was different from that present in the vaccine. The reduction in AMO was 27%. Gagliani et al.,\textsuperscript{79} observed reductions of 18 to 20% in the number of medical consultations for episodes of acute respiratory infections in children vaccinated with the attenuated influenza vaccine.

Jefferson et al.,\textsuperscript{80} reviewed the efficacy of the attenuated vaccine in healthy children, reporting it at 79%. These authors report that the efficacy of the inactivated vaccine is 65%. The effectiveness of vaccination was 38% for the attenuated vaccine and 28% for the inactivated vaccine, in both cases for children older than 2 years. Efficacy for children younger than 2 years was not studied systematically, with the exception of the investigations into AMO episodes mentioned above.

Population-based studies of the impact of influenza vaccination with the inactivated vaccine in schoolchildren showed control of influenza epidemics with reductions in the total number of cases and in viral dissemination.\textsuperscript{81} The same result was recently reported for the attenuated vaccine by Piedra et. al.,\textsuperscript{82} who observed reductions in the number of medical consultations in unvaccinated people when vaccination coverage reached 25% of schoolchildren. In Japan, the national program for influenza vaccination of schoolchildren was associated with reduced mortality by influenza among the elderly.\textsuperscript{83} Universal influenza vaccination is currently under debate as a more effective alternative for preventing the disease.\textsuperscript{68,84}

Final comments

Acute respiratory infections are a worldwide public health problem, with significant impact on morbidity and mortality in children under 5 years of age and in other high-risk populations.\textsuperscript{31} Vaccination is an effective measure for controlling these diseases, as has been observed for measles and invasive \textit{Haemophilus influenzae} type B infections.\textsuperscript{85} Vaccination against influenza has surfaced as a new weapon in the fight to prevent ARI in children. With the epidemiological data that are currently available on the impact of this agent on the pediatric age group, we can infer that the benefits of vaccination would be reductions in morbidity, observed through the reductions in number of hospital admissions, medical consultations and antibiotic prescriptions for healthy children during influenza epidemics.\textsuperscript{84}

Without doubt, a major impact would be felt from an influenza immunization program that covered all schoolchildren, however, the vaccination of small groups, particularly through programs in partnership with businesses or health insurance plans, would be a good start for assessing the impact of influenza vaccination.\textsuperscript{68,84} Secondary benefits, such as reductions in parents’ absenteeism from work, reduced circulation of influenza viruses at daycare centers, and even reductions in secondary cases among family members would be another impact of vaccination against influenza in children, which would make vaccination more cost-effective.

Therefore, the current recommendation on influenza vaccination for children is that pediatricians should indicate the vaccination of all children over 6 months old with risk factors and for all children aged 6 to 23 months. For all other age groups, it is suggested that the vaccine be offered, emphasizing the benefits of vaccination for the prevention of influenza infections and their complications.

Conflict of interest

Otávio A. L. Cintra declares that he is a member of the speaker’s bureau and works on research protocols for Sanofi-Pasteur do Brasil. He further declares that he is also a member of the speaker’s bureau for GlaxoSmithKline do Brasil.
Influenza vaccine in children – Cintra OAL & Rey LC


Correspondence:
Otavio L. A. Cintra
Rua A Rui Barbosa, 1775
CEP 14015-120 – Ribeirão Preto, SP – Brazil
Tel.: +55 (16) 3602.2925, +55 (16) 3625.1535,
+55 (16) 3635.0576
Fax: +55 (16) 3633.3935
E-mail: oacintra@uol.com.br